The platform of new drugs for the polycystic kidney disease is increasing on account of less number of drugs available for treatment of the disease. Polycystic kidney disease is a form of rare disease and the drugs which are available for treatment, have an adverse effect on the health of patients. Currently, the prevalence of polycystic kidney disease in the U.S. ranges from 1 in 400 to 1 in 1000 which resulted in end stage renal disease by the age of 53. Around 600,000 patients are suffering from renal disease, out of which 2,000 patients start a renal replacement therapy every year. Increasing awareness in health-related issues is another factor responsible for the growth of polycystic kidney disease therapeutics pipeline.
Polycystic kidney disease is a disease which affects kidney along with other organs, in which development of cyst interrupts the ability to filter the waste products from blood. Enlargement of cyst may lead to kidney failure which can in turn impact other organs. Polycystic kidney disease is mostly related to high blood pressure, blood in urine, pain in back, kidney stones and heart valve abnormalities. People with polycystic kidney disease are at a risk of developing aneurysm in aorta or in blood vessels in base of the brain. Polycystic kidney disease is of two types as, autosomal dominant polycystic kidney disease, which begins in adulthood and autosomal recessive polycystic kidney disease. Autosomal dominant polycystic kidney disease can also be categorised as type 1 and type 2 subjected to genetic cause. The autosomal recessive polycystic kidney disease is a very rare and lethal form of disease, and its symptoms start appearing during birth or infancy. Polycystic kidney disease occurs mainly due to mutations in PKD1, PKD2 and PKHD1 genes.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/polycystic-kidney-disease-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of polycystic kidney disease therapeutics include Otsuka Pharmaceutical Co., Ltd., Alexion Pharmaceuticals Inc, Kyowa Hakko Kirin Co., Ltd., Catalyst Biosciences, Inc., Amgen, Inc., Angion Biomedica Corporation, Amyndas Pharmaceuticals LLC, Apellis Pharmaceuticals, Inc, Biogen, Inc, Astellas Pharma, Inc., Corline Biomedical AB, CSL Limited, Digna Biotech, S.L., GlaxoSmithKline Plc, Grifols, S.A.